Why Alamar Biosciences, Inc.’s (ALMR) Stock Is Up 5.46%
As of Tuesday, August 25, Alamar Biosciences, Inc.’s ALMR share price has surged by 5.46%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Stock Evaluator: Alamar Biosciences, Inc. (ALMR)
Alamar Biosciences, Inc. ALMR
$30.49
1.13
3.85%
September 2, 2026 4:00:00 PM
EST
Volume: 241,144
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company’s offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.
Commentary & Analysis
Why Alamar Biosciences, Inc.’s (ALMR) Stock Is Up 9.86%
As of Wednesday, August 19, Alamar Biosciences, Inc.’s ALMR share price has surged by 9.86%, which has investors questioning if this is right time to sell.Jenna Brashear
Is Alamar Biosciences, Inc. (ALMR) Stock a Good Investment?
Learn more about Alamar Biosciences, Inc.'s (ALMR) stock grades for Estimate Revisions and determine whether this Life Sciences Tools & Services stock meets your investment needs.Jenna Brashear
Why Alamar Biosciences, Inc.’s (ALMR) Stock Is Down 6.43%
As of Wednesday, August 12, Alamar Biosciences, Inc.’s ALMR share price has dipped by 6.43%, which has investors questioning if this is right time to buy.Michael Rose
Why Alamar Biosciences, Inc.’s (ALMR) Stock Is Up 14.11%
As of Tuesday, August 11, Alamar Biosciences, Inc.’s ALMR share price has surged by 14.11%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | ALMR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,115.8 | $3,681.2 | 54% |
|
| Shares Out (Mil) | 58.7 | 98.2 | 51% |
|
| Institutional Ownership | 73.5% | 89.6% | 44% |
|
| Float (Mil) | 36.2 | 70.7 | 40% |
|
| Beta | na | 1.19 | na |
|
| Avg Daily Volume (000s) | 296 | 652 | 51% |
|
| Price Change (52-week) |
na | 87.5% | na |
|
| Growth | ALMR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 7.8% | na |
|
| Net Income (5yr) | na | (11.2%) | na |
|
| EPS (5yr) | na | 2.5% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.201) | ($1.164) | ($0.542) | |
| Month Ago EPS | ($0.209) | ($1.456) | ($0.704) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | ($0.209) | ($1.456) | ($0.704) | |
| Year/Year Chg | (10.7%) | (55.0%) | (93.5%) | |
| Financials | ALMR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $100 | $810 | 26% |
|
| Net Income (TTM) (Mil) | ($50) | ($31) | 16% |
|
| EPS (TTM) | ($2.098) | ($0.300) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($60) | $56 | 9% |
|
| Net Cash Flow (TTM) (Mil) | $115 | $3 | 79% |
|
| Long-Term Debt (Q1) (Mil) | $49 | $264 | 39% |
|
| Enterprise Value (Q1) (Mil) | $1,932 | $3,795 | 48% |
|
| Valuation | ALMR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.76 | 3.86 | 84% |
|
| P/E | na | 38.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.8 | na |
|
| Ratios | ALMR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 58.7% | 47.6% | 71% |
|
| Net Margin | (49.5%) | (2.6%) | 12% |
|
| ROA | (25.4%) | (4.0%) | 18% |
|
| ROE | (31.7%) | (7.7%) | 19% |
|
| Liabilities to Assets | 20.0% | 41.1% | 13% |
|
| F-Score | 0 | 5 | na |
|
Alamar Biosciences, Inc. did not pass any screens on 9/2/2026.
